Corporate Profile

We are a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology.

We have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation.

Leveraging these assets and expertise, we are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs.

Two royalty bearing collaborations with AbbVie and Boehringer Ingelheim

Two innovative clinical programs: NATIVE and IMPROVES

Pre-clinical pipeline in oncology and fibrosis

State of the art R&D capabilities inherited from Abbott, Solvay, Fournier

Financial Information

Upcoming Events

February 13, 2019

Publication of revenues and cash position
as of December 31, 2018

February 27, 2019

2018 annual financial results

Share Information

€4.05 -0.74%

Last update: May 29, 2020 at 17:35 CET

Open: €4.09
Previous close: €4.08

Day High: €4.145
Day Low: €4.0

Regulated Information

April 16, 2018

April 16, 2018

May 17, 2017

January 12, 2017


April 18, 2019

April 9, 2019

March 8, 2019


Inventiva was co-founded by Frédéric Cren, Chairman, CEO and Co-Founder and Pierre Broqua, Chief Scientific Officer in Dijon in 2012.

Both have strong expertise within the areas of research, development and strategy and held senior research and executive positions at both Fournier and Solvay prior to founding Inventiva.

Investor Contacts

50 rue de Dijon
21121 Daix, France
Tel: +33 (0)3 80 44 75 00

LifeSci Advisors
Investor relations – Monique Kosse
Tel: +1 212 915 3820